Search

Your search keyword '"Sugimoto, Tohru"' showing total 180 results

Search Constraints

Start Over You searched for: Author "Sugimoto, Tohru" Remove constraint Author: "Sugimoto, Tohru" Database Unpaywall Remove constraint Database: Unpaywall
180 results on '"Sugimoto, Tohru"'

Search Results

1. Supplementary Data from Trastuzumab Activates Allogeneic or Autologous Antibody-Dependent Cellular Cytotoxicity against Malignant Rhabdoid Tumor Cells and Interleukin-2 Augments the Cytotoxicity

2. Supplementary Figure S2 from Circulating Methylated-DCR2 Gene in Serum as an Indicator of Prognosis and Therapeutic Efficacy in Patients with MYCN Nonamplified Neuroblastoma

3. Data from Circulating Methylated-DCR2 Gene in Serum as an Indicator of Prognosis and Therapeutic Efficacy in Patients with MYCN Nonamplified Neuroblastoma

4. Supplementary Figure S1 from Circulating Methylated-DCR2 Gene in Serum as an Indicator of Prognosis and Therapeutic Efficacy in Patients with MYCN Nonamplified Neuroblastoma

6. Data from Circulating Methylated-DCR2 Gene in Serum as an Indicator of Prognosis and Therapeutic Efficacy in Patients with MYCN Nonamplified Neuroblastoma

7. Supplementary Table 1 from Circulating Methylated-DCR2 Gene in Serum as an Indicator of Prognosis and Therapeutic Efficacy in Patients with MYCN Nonamplified Neuroblastoma

9. Supplementary Figure S1 from Circulating Methylated-DCR2 Gene in Serum as an Indicator of Prognosis and Therapeutic Efficacy in Patients with MYCN Nonamplified Neuroblastoma

10. Supplementary Table 1 from Circulating Methylated-DCR2 Gene in Serum as an Indicator of Prognosis and Therapeutic Efficacy in Patients with MYCN Nonamplified Neuroblastoma

11. Supplementary Data from Trastuzumab Activates Allogeneic or Autologous Antibody-Dependent Cellular Cytotoxicity against Malignant Rhabdoid Tumor Cells and Interleukin-2 Augments the Cytotoxicity

12. Supplementary Figure S2 from Circulating Methylated-DCR2 Gene in Serum as an Indicator of Prognosis and Therapeutic Efficacy in Patients with MYCN Nonamplified Neuroblastoma

13. Supplementary Table and 3 Figures from Methylation-Associated Silencing of the Nuclear Receptor 1I2 Gene in Advanced-Type Neuroblastomas, Identified by Bacterial Artificial Chromosome Array-Based Methylated CpG Island Amplification

14. Supplementary Table and 3 Figures from Methylation-Associated Silencing of the Nuclear Receptor 1I2 Gene in Advanced-Type Neuroblastomas, Identified by Bacterial Artificial Chromosome Array-Based Methylated CpG Island Amplification

18. Rare MYC-amplified Neuroblastoma With Large Cell Histology

20. Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma

22. Potential of boron neutron capture therapy (BNCT) for malignant peripheral nerve sheath tumors (MPNST)

23. Boron neutron capture therapy (BNCT) as a new approach for clear cell sarcoma (CCS) treatment: Trial using a lung metastasis model of CCS

24. Boron neutron capture therapy as new treatment for clear cell sarcoma: Trial on different animal model

26. Boron neutron capture therapy (BNCT) selectively destroys human clear cell sarcoma in mouse model

30. Preoperative analysis of 11q loss using circulating tumor-released DNA in serum: A novel diagnostic tool for therapy stratification of neuroblastoma

31. Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression

39. A novel PAX3 rearrangement in embryonal rhabdomyosarcoma

41. Circulating Methylated-DCR2Gene in Serum as an Indicator of Prognosis and Therapeutic Efficacy in Patients withMYCNNonamplified Neuroblastoma

46. Effectiveness of screening for neuroblastoma at 6 months of age: a retrospective population-based cohort study

48. Trastuzumab Activates Allogeneic or Autologous Antibody-Dependent Cellular Cytotoxicity against Malignant Rhabdoid Tumor Cells and Interleukin-2 Augments the Cytotoxicity

Catalog

Books, media, physical & digital resources